Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
C4 Therapeutics, Inc. (CCCC) had Consolidated Net Income/Loss of $-105.32M for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
$35.58M |
|
$-105.32M |
|
-- |
|
$35.58M |
|
$155.20M |
|
$-119.61M |
|
$14.43M |
|
$-105.19M |
|
$-105.19M |
|
$-105.32M |
|
$-105.32M |
|
|
Consolidated Net Income/Loss |
$-105.32M |
$-105.32M |
|
$-119.61M |
|
$-123.19M |
|
69.37M |
|
69.37M |
|
$-1.52 |
|
$-1.52 |
|
| Balance Sheet Financials | |
$257.77M |
|
$5.84M |
|
$91.83M |
|
$349.60M |
|
$45.18M |
|
-- |
|
$88.44M |
|
$133.62M |
|
$215.99M |
|
$215.99M |
|
$215.99M |
|
70.63M |
|
| Cash Flow Statement Financials | |
$-65.16M |
|
$-51.27M |
|
$45.34M |
|
$130.03M |
|
$58.94M |
|
$-71.09M |
|
$29.66M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
5.71 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-336.15% |
|
-336.15% |
|
-346.20% |
|
-295.60% |
|
-295.96% |
|
$-65.34M |
|
-- |
|
-- |
|
-- |
|
0.10 |
|
-- |
|
11.47 |
|
31.82 |
|
-48.76% |
|
-48.76% |
|
-30.12% |
|
-48.76% |
|
$3.06 |
|
$-0.94 |
|
$-0.94 |
|